[{"edinetCode":"E00932","endDate":"2017\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":7372.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":421046000.0,"sharesOwendPercent":0.7522,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":43.37,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2018\/3\/22","stockCode":4519,"accountingYear":"2017年（自　2017年１月１日　至　2017年12月31日）","accountingYearStart":"2017\/1\/1","accountingYearEnd":"2017\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00932","endDate":"2018\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":7432.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":429978000.0,"sharesOwendPercent":0.7857,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":37.73,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2019\/3\/28","stockCode":4519,"accountingYear":"2018年（自　2018年１月１日　至　2018年12月31日）","accountingYearStart":"2018\/1\/1","accountingYearEnd":"2018\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00932","endDate":"2019\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/4\/26","stockCode":4519,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00932","endDate":"2019\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":431132000.0,"sharesOwendPercent":0.7875,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q2r","submitDate":"2019\/7\/26","stockCode":4519,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00932","endDate":"2019\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2019\/10\/30","stockCode":4519,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00932","endDate":"2019\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":7394.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":428793000.0,"sharesOwendPercent":0.7831,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1058920000000.0,"currentAssets":699680000000.0,"fixedAsset":null,"tangibleFixedAssets":255559000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":204930000000.0,"currentLiabilities":179268000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":266071000000.0,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":35.02,"roe":null,"cashFlowFromOperatingActivities":206641000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-81741000000.0,"cashFlowFromFinancialActivities":-66872000000.0,"changesInCashAndCashEquivalents":57081000000.0,"列1":"asr","submitDate":"2020\/3\/30","stockCode":4519,"accountingYear":"2019年（自　2019年１月１日　至　2019年12月31日）","accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00932","endDate":"2020\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1045610000000.0,"currentAssets":663251000000.0,"fixedAsset":null,"tangibleFixedAssets":277442000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":191486000000.0,"currentLiabilities":167207000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":61272000000.0,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":5009000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-16982000000.0,"cashFlowFromFinancialActivities":-51966000000.0,"changesInCashAndCashEquivalents":-65230000000.0,"列1":"q1r","submitDate":"2020\/4\/28","stockCode":4519,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00932","endDate":"2020\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":434529000.0,"sharesOwendPercent":0.793,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1072140000000.0,"currentAssets":695612000000.0,"fixedAsset":null,"tangibleFixedAssets":275270000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":166202000000.0,"currentLiabilities":141824000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":131841000000.0,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":55373000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-7680000000.0,"cashFlowFromFinancialActivities":-54285000000.0,"changesInCashAndCashEquivalents":-7337000000.0,"列1":"q2r","submitDate":"2020\/7\/30","stockCode":4519,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00932","endDate":"2020\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1136110000000.0,"currentAssets":742331000000.0,"fixedAsset":null,"tangibleFixedAssets":288254000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":210838000000.0,"currentLiabilities":184678000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":201200000000.0,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":132814000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-57072000000.0,"cashFlowFromFinancialActivities":-97176000000.0,"changesInCashAndCashEquivalents":-21229000000.0,"列1":"q3r","submitDate":"2020\/10\/28","stockCode":4519,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00932","endDate":"2020\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":7555.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":1300373000.0,"sharesOwendPercent":0.791,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1235500000000.0,"currentAssets":834906000000.0,"fixedAsset":null,"tangibleFixedAssets":289218000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":255495000000.0,"currentLiabilities":236070000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":273465000000.0,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":42.12,"roe":null,"cashFlowFromOperatingActivities":205035000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-98312000000.0,"cashFlowFromFinancialActivities":-99497000000.0,"changesInCashAndCashEquivalents":8393000000.0,"列1":"asr","submitDate":"2021\/3\/23","stockCode":4519,"accountingYear":"2020年（自　2020年１月１日　至　2020年12月31日）","accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00932","endDate":"2021\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1144630000000.0,"currentAssets":740971000000.0,"fixedAsset":null,"tangibleFixedAssets":291379000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":162019000000.0,"currentLiabilities":144103000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":55338000000.0,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":46541000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-46896000000.0,"cashFlowFromFinancialActivities":-51124000000.0,"changesInCashAndCashEquivalents":-50284000000.0,"列1":"q1r","submitDate":"2021\/4\/27","stockCode":4519,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00932","endDate":"2021\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":1298077000.0,"sharesOwendPercent":0.7894,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1275770000000.0,"currentAssets":857123000000.0,"fixedAsset":null,"tangibleFixedAssets":310588000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":223709000000.0,"currentLiabilities":205910000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":123397000000.0,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":103002000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-76595000000.0,"cashFlowFromFinancialActivities":-53384000000.0,"changesInCashAndCashEquivalents":-25202000000.0,"列1":"q2r","submitDate":"2021\/7\/29","stockCode":4519,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00932","endDate":"2021\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1353360000000.0,"currentAssets":913595000000.0,"fixedAsset":null,"tangibleFixedAssets":327598000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":262714000000.0,"currentLiabilities":244669000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":227591000000.0,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":184669000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-101760000000.0,"cashFlowFromFinancialActivities":-104428000000.0,"changesInCashAndCashEquivalents":-19816000000.0,"列1":"q3r","submitDate":"2021\/10\/27","stockCode":4519,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00932","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":73201,"settlementDate":"2022\/12\/31","submitterName":"中外製薬株式会社","submitterNameEnglish":"CHUGAI PHARMACEUTICAL CO., LTD.","submitterNameKana":"チュウガイセイヤクカブシキガイシャ","location":"北区浮間五丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0}]